GE HealthCare Technologies Inc. (GEHC) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GE HealthCare Technologies Inc. (GEHC), Healthcare sektöründe faaliyet gösteriyor, son olarak 71.42$'dan işlem görüyor ve 33B piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 52/100 puan alıyor.
Son analiz: 9 Şub 2026GE HealthCare Technologies Inc. (GEHC) Sağlık ve Boru Hattı Genel Bakışı
GE HealthCare Technologies Inc. (GEHC) is a leading global innovator in medical technology, offering a comprehensive suite of imaging, ultrasound, patient care, and pharmaceutical diagnostics solutions, driving precision health and improved patient outcomes with a strong focus on digital innovation and global reach.
Yatırım Tezi
GE HealthCare presents a notable research candidate due to its leading position in the growing medical technology market. With a market capitalization of $36.76 billion and a P/E ratio of 21.92, the company demonstrates financial stability and growth potential. The company's diversified portfolio across imaging, ultrasound, patient care, and pharmaceutical diagnostics provides resilience and multiple avenues for growth. Key value drivers include increasing demand for advanced medical imaging and diagnostic solutions, driven by an aging global population and rising healthcare expenditures. Upcoming catalysts include continued innovation in digital health solutions and expansion into emerging markets. The company's commitment to innovation and strategic partnerships positions it for sustained growth and enhanced shareholder value.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $36.76B reflects substantial investor confidence in GE HealthCare's market position and future growth prospects.
- P/E Ratio of 21.92 indicates a reasonable valuation relative to earnings, suggesting potential for appreciation.
- Profit Margin of 8.6% demonstrates solid profitability and efficient operations within the healthcare technology sector.
- Gross Margin of 43.5% highlights the company's ability to maintain strong pricing power and manage production costs effectively.
- Dividend Yield of 0.17% provides a modest income stream for investors, with potential for future increases as the company grows.
Rakipler & Benzerleri
Güçlü Yönler
- Diversified product portfolio across imaging, ultrasound, patient care, and pharmaceutical diagnostics.
- Strong global presence and established relationships with healthcare providers.
- Significant investment in research and development, driving innovation.
- Experienced management team with a proven track record.
Zayıflıklar
- Dependence on healthcare spending and reimbursement policies.
- Exposure to regulatory risks and compliance requirements.
- Potential for product recalls and liability claims.
- Competition from established and emerging medical technology companies.
Katalizörler
- Ongoing: Continued innovation in digital health solutions, including AI-powered diagnostic tools and remote patient monitoring systems.
- Ongoing: Expansion into emerging markets, particularly in Asia-Pacific and Latin America.
- Upcoming: Potential for new product launches and regulatory approvals.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
Riskler
- Potential: Economic downturns and budget constraints in healthcare systems could reduce demand for GE HealthCare's products and services.
- Ongoing: Technological obsolescence and disruption from new entrants could erode GE HealthCare's competitive advantage.
- Ongoing: Changes in healthcare regulations and reimbursement policies could negatively impact GE HealthCare's profitability.
- Potential: Product recalls and liability claims could damage GE HealthCare's reputation and financial performance.
Büyüme Fırsatları
- Expansion in Emerging Markets: GE HealthCare has a significant opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and demand for advanced medical technologies. By leveraging its existing infrastructure and partnerships, GE HealthCare can increase its market share and drive revenue growth in these high-potential markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- Digital Health Solutions: GE HealthCare is investing heavily in digital health solutions, including AI-powered diagnostic tools, remote patient monitoring systems, and data analytics platforms. The market for digital health solutions is growing rapidly, driven by the increasing adoption of telehealth and the need for more efficient and personalized healthcare. GE HealthCare's digital offerings can improve patient outcomes, reduce healthcare costs, and generate recurring revenue streams. This is an ongoing opportunity with continuous development.
- Strategic Partnerships and Acquisitions: GE HealthCare can pursue strategic partnerships and acquisitions to expand its product portfolio, enter new markets, and enhance its technological capabilities. Collaborating with other companies can accelerate innovation and provide access to complementary technologies and expertise. Targeted acquisitions can fill gaps in GE HealthCare's product offerings and strengthen its competitive position. This is an ongoing strategy for growth and market leadership.
- Innovation in Pharmaceutical Diagnostics: The Pharmaceutical Diagnostics segment offers significant growth potential through the development of new contrast agents and molecular imaging agents. These agents enhance the visibility of tissues and structures during imaging exams, improving diagnostic accuracy and patient outcomes. GE HealthCare can invest in research and development to create novel agents that address unmet clinical needs and expand its market share in the pharmaceutical diagnostics industry. This is an ongoing area of research and development.
- Advancements in Ultrasound Technology: GE HealthCare's Ultrasound segment can drive growth through continuous innovation in ultrasound technology. This includes developing more portable and affordable ultrasound devices, improving image quality and resolution, and expanding the applications of ultrasound in various clinical settings. The company can leverage its expertise in ultrasound to create new solutions for point-of-care diagnostics, women's health, and cardiovascular imaging. This is an ongoing area of focus for the company.
Fırsatlar
- Expansion in emerging markets with growing healthcare demand.
- Development of new digital health solutions and AI-powered diagnostic tools.
- Strategic partnerships and acquisitions to expand product portfolio.
- Increasing adoption of telehealth and remote patient monitoring.
Tehditler
- Economic downturns and budget constraints in healthcare systems.
- Technological obsolescence and disruption from new entrants.
- Changes in healthcare regulations and reimbursement policies.
- Increased competition and pricing pressure.
Rekabet Avantajları
- Strong brand reputation and established market presence in the medical technology industry.
- Extensive portfolio of medical imaging and diagnostic solutions.
- Significant investment in research and development, leading to technological innovation.
- Global sales and service network, providing comprehensive support to customers.
- High switching costs for customers due to the complexity and integration of medical equipment.
GEHC Hakkında
GE HealthCare Technologies Inc., incorporated in 2022 and headquartered in Chicago, Illinois, is a spin-off from General Electric, inheriting a legacy of innovation in medical technology. The company develops, manufactures, and markets a wide array of products, services, and digital solutions used in the diagnosis, treatment, and monitoring of patients across the globe. GE HealthCare operates through four key segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides advanced imaging technologies such as molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, including specialized solutions for women's health. The Ultrasound segment offers solutions for screening, diagnosis, treatment, and monitoring of diseases through radiology, primary care, women's health, cardiovascular applications, and point-of-care ultrasound. The Patient Care Solutions segment focuses on medical devices, consumable products, services, and digital solutions for patient monitoring, anesthesia delivery, respiratory care, diagnostic cardiology, and maternal-infant care. The Pharmaceutical Diagnostics segment supplies diagnostic agents, including contrast media and molecular imaging agents, to the radiology and nuclear medicine industry, enhancing the visibility of tissues and structures during imaging exams. GE HealthCare's global presence extends across the United States, Canada, Europe, the Middle East, Africa, China, and other international markets. With a workforce of 53,000 employees, the company is committed to improving patient outcomes and driving innovation in healthcare technology.
Ne Yaparlar
- Develop and manufacture medical imaging equipment, including MRI, CT, and X-ray machines.
- Provide ultrasound systems for various clinical applications.
- Offer patient monitoring solutions for hospitals and healthcare facilities.
- Produce diagnostic agents and contrast media for medical imaging.
- Provide healthcare IT solutions and software for data management and analysis.
- Offer services and support for their medical equipment.
- Develop digital solutions to improve patient outcomes and healthcare efficiency.
İş Modeli
- Sales of medical equipment and related products to hospitals, clinics, and other healthcare providers.
- Recurring revenue from service contracts and maintenance agreements.
- Sales of diagnostic agents and contrast media to radiology and nuclear medicine departments.
- Software licensing and subscription fees for healthcare IT solutions.
Sektör Bağlamı
GE HealthCare operates in the medical technology industry, which is characterized by continuous innovation, increasing demand for advanced diagnostic and treatment solutions, and evolving regulatory landscapes. The global medical device market is projected to reach hundreds of billions of dollars in the coming years, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing healthcare spending. GE HealthCare competes with companies like A (Agilent Technologies), ALC (Alcon), CAH (Cardinal Health), HUM (Humana), and INSM (Insmed) in various segments. The company's focus on digital health solutions and precision medicine positions it well to capitalize on emerging trends and maintain a competitive edge.
Kilit Müşteriler
- Hospitals and healthcare systems
- Diagnostic imaging centers
- Radiology and nuclear medicine departments
- Private practice physicians
- Research institutions
Finansallar
Grafik & Bilgi
GE HealthCare Technologies Inc. (GEHC) hisse senedi fiyatı: $71.42 (-0.23, -0.32%)
Son Haberler
-
All You Need to Know About GE HealthCare (GEHC) Rating Upgrade to Buy
zacks.com · 27 Mar 2026
-
GE HealthCare advances imaging lineup with photon-counting CT system clearance
Yahoo! Finance: GEHC News · 24 Mar 2026
-
GE HealthCare wins FDA nod for photon-counting CT technology
Yahoo! Finance: GEHC News · 24 Mar 2026
-
GE HealthCare Secures FDA Clearance for Photonova Spectra CT System
MT Newswires · 23 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GEHC için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $91.11
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GEHC'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
All You Need to Know About GE HealthCare (GEHC) Rating Upgrade to Buy
GE HealthCare advances imaging lineup with photon-counting CT system clearance
GE HealthCare wins FDA nod for photon-counting CT technology
GE HealthCare Secures FDA Clearance for Photonova Spectra CT System
Yatırımcılar GE HealthCare Technologies Inc. (GEHC) Hakkında Ne Soruyor
GEHC için değerlendirilmesi gereken temel faktörler nelerdir?
GE HealthCare Technologies Inc. (GEHC) şu anda yapay zeka skoru 52/100, orta puanı gösteriyor. Hisse 19.4x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) altında, potansiyel değer sinyali. Analist hedefi $91.11 ($71.42'dan +28%). Temel güçlü yan: Diversified product portfolio across imaging, ultrasound, patient care, and pharmaceutical diagnostics.. İzlenmesi gereken birincil risk: Potential: Economic downturns and budget constraints in healthcare systems could reduce demand for GE HealthCare's products and services.. Bu bir finansal tavsiye değildir.
GEHC MoonshotScore'u nedir?
GEHC şu anda MoonshotScore'da 52/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GEHC verileri ne sıklıkla güncellenir?
GEHC fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GEHC hakkında ne diyor?
Analistler, GEHC için $91.11 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($71.42) yukarı yönlü %28 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
GEHC'a yatırım yapmanın riskleri nelerdir?
GEHC için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Economic downturns and budget constraints in healthcare systems could reduce demand for GE HealthCare's products and services.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GEHC'ın P/E oranı nedir?
GE HealthCare Technologies Inc. (GEHC)'nın son P/E oranı 19.4, ki bu da piyasa ortalamasının altında, bu da göreli değeri gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
GEHC aşırı değerli mi, yoksa düşük değerli mi?
GE HealthCare Technologies Inc. (GEHC)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 19.4. Analist hedefi $91.11 (mevcut fiyattan +28%), analistlerin yukarı yönlü potansiyel gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GEHC'ın temettü verimi nedir?
GE HealthCare Technologies Inc. (GEHC) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the latest available information.
- Future performance is subject to market conditions and company-specific factors.
- This analysis is for informational purposes only and does not constitute investment advice.